Hong Kong is George Clinical’s East Asia hub, overseeing our operations in Taiwan and Malaysia.
Hong Kong is George Clinical’s East Asia hub, overseeing our operations in Malaysia, Singapore, South Korea, Taiwan, Thailand, Philippines, Indonesia and Vietnam.
Hong Kong has a long history of international research with sophisticated infrastructure and resources across all phases. A small, densely populated area, Hong Kong’s world-class hospitals offer excellent recruitment potential. Hong Kong has a long and impressive track record of conducting global clinical trials. Since the introduction of ICH GCP in 1996, Hong Kong has participated in over 1000 global clinical trials. Hong Kong has had a history of high-quality clinical research output and plays a role in scientific leadership in Asia.
Hong Kong has excellent infrastructure in terms of transportation, workforce and legal framework. Hong Kong has an outstanding healthcare system, as indicated by one of the lowest infant mortality rates and the longest life expectancy in the world. There are 42 public hospitals that provide 90% of the medical care in Hong Kong.
Hong Kong is officially recognized by China State Food and Drug Administration for conducting clinical trials for drug registration purposes in mainland China in certain therapeutic areas. There is strong government support for clinical research, with the recent example being the set up of two Phase I centers at leading teaching hospitals in Hong Kong.
Clinical trial data from Hong Kong can be used to file new drug applications, making Hong Kong a gateway to mainland China.
|Official Language||Chinese (Traditional Chinese), English|
|Hospital Records Language||English|
|Electronic Hospital Records||Yes, stored centrally|
|Site Network||42 public hospitals, which provide 90% of medical care in Hong Kong|
|In-country services||Project Management